Ernexa Therapeutics (ERNA) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to -$3.0 million.
- Ernexa Therapeutics' Enterprise Value rose 2854.13% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.0 million, marking a year-over-year increase of 2854.13%. This contributed to the annual value of -$1.7 million for FY2024, which is 8903.27% up from last year.
- Per Ernexa Therapeutics' latest filing, its Enterprise Value stood at -$3.0 million for Q3 2025, which was up 2854.13% from -$4.3 million recorded in Q2 2025.
- Over the past 5 years, Ernexa Therapeutics' Enterprise Value peaked at -$1.7 million during Q4 2024, and registered a low of -$50.2 million during Q2 2021.
- In the last 5 years, Ernexa Therapeutics' Enterprise Value had a median value of -$13.0 million in 2022 and averaged -$13.9 million.
- As far as peak fluctuations go, Ernexa Therapeutics' Enterprise Value plummeted by 86719.0% in 2021, and later skyrocketed by 8903.27% in 2024.
- Over the past 5 years, Ernexa Therapeutics' Enterprise Value (Quarter) stood at -$24.4 million in 2021, then grew by 19.47% to -$19.6 million in 2022, then grew by 19.71% to -$15.8 million in 2023, then skyrocketed by 89.03% to -$1.7 million in 2024, then plummeted by 76.23% to -$3.0 million in 2025.
- Its Enterprise Value was -$3.0 million in Q3 2025, compared to -$4.3 million in Q2 2025 and -$1.9 million in Q1 2025.